BOSTON SCIENTIFIC CORP (BSX)       45.91  -0.44 (-0.95%)

45.91  -0.44 (-0.95%)

US1011371077 - Common Stock - After market: 45.91 0 (0%)

BOSTON SCIENTIFIC CORP45.91

NYSE:BSX (1/27/2023, 7:04:01 PM)-0.44 (-0.95%)

After market: 45.91 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Health Care Equipment & Supplies

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 10-26 2022-10-26/bmo Earnings (Next) 01-31 2023-01-31
Ins Owners 0.23% Inst Owners 91.58%
Market Cap 65.76B Shares 1.43B
PE 26.85 Fwd PE 23.43
Dividend Yield N/A Analysts 83.53
IPO 05-19 1992-05-19

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BSX Daily chart

Company Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. The company is headquartered in Marlborough, Massachusetts and currently employs 41,000 full-time employees. The Company’s business segments include MedSurg, Rhythm and Neuro, and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Pelvic Health. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal (GI) and pulmonary conditions. Its Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions. The Rhythm and Neuro segment include Cardiac Rhythm Management (CRM) and Electrophysiology. Its CRM develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions.

Company Info

BOSTON SCIENTIFIC CORP

300 Boston Scientific Way

Marlborough MASSACHUSETTS 01752

P: 15086834000.0

CEO: Michael F. Mahoney

Employees: 41000

Website: https://www.bostonscientific.com/

BSX News

News Image3 days ago - ChartmillGood technical signals and a possible breakout for BOSTON SCIENTIFIC CORP.News Image4 days ago - ChartmillWill BOSTON SCIENTIFIC CORP breakout?News Image6 days ago - Market News VideoNoteworthy Tuesday Option Activity: DLR, COF, BSXNews Image7 days ago - Kahn Swick & Foti, LLCBOSTON SCIENTIFIC INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSXNews Image9 days ago - Seeking AlphaDisinflation could be a slow roll - take shelter in these stocks

The stock market has moved higher in 2023 with some investors appearing to price in a quick drop in inflation in 2023 or an immaculate disinflation scenario. Read more.

News Image17 days ago - Kahn Swick & Foti, LLCAPOLLO ENDOSURGERY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN

/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...

BSX Twits

Here you can normally see the latest stock twits on BSX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example